Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir) – Expanded indication
March 2, 2020 - The FDA approved Janssen’s Symtuza (darunavir/cobicistat/emtricitabine/tenofovir), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.
Top